As a therapeutic area, allergy is sometimes considered to be slightly ‘awkward’: disease-modifying treatments are challenging to develop with recent high-profile failures in the UK markets; the regulatory backdrop is somewhat dominated in Europe by the German TAV process; and the US doesn’t yet represent the market opportunity in allergy as it does traditional bio/pharma. If investors were to look a little closer, however, they would see Allergy Therapeutics building a signi
